Biofrontera to Participate in Two Upcoming Investor Conferences
November 26 2018 - 1:08PM
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the
“Company”), an international biopharmaceutical company, today
announced its participation in two upcoming conferences.
Prof. Dr. Hermann Lübbert, Biofrontera’s Chief
Executive Officer, and Thomas Schaffer, Chief Financial Officer,
are scheduled to participate at the Benchmark Microcap Discovery
Conference being held on November 29, 2018 at the Palmer House
Hilton in Chicago, IL.
Mr. Schaffer will also present at the 11th
Annual LD Micro Main Event being held on December 4-6, 2018 at the
Luxe Sunset Boulevard Hotel in Los Angeles, CA.
Event: Benchmark Microcap Discovery
ConferenceFormat: 1x1
MeetingsDate: Thursday, November 29, 2018
Location: Palmer House Hilton, Chicago,
ILEvent: 11th Annual LD Micro Main
EventFormat: Presentation & 1x1
MeetingsDate: Tuesday, December 4,
2018Time: 9:30 am PTLocation:
Luxe Sunset Boulevard Hotel, Los Angeles, CA: Track 4
About Biofrontera:
Biofrontera AG is an international
biopharmaceutical company specializing in the development and
commercialization of a platform of pharmaceutical products for the
treatment of dermatological conditions and diseases caused
primarily by exposure to sunlight that results in sun damage to the
skin. Biofrontera's approved products focus on the treatment in the
U.S. and Europe of actinic keratoses, which are skin lesions that
can sometimes lead to skin cancer, as well as the treatment of
certain forms of basal cell carcinoma in the European Union.
American Depositary Shares representing Biofrontera's ordinary
shares are listed on the NASDAQ Capital Market under the symbol
"BFRA", and Biofrontera's ordinary shares are listed in the
Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is
also available at www.biofrontera.com.
Forward Looking Statements:
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995 regarding the public offering and the
intended use of proceeds from the offering. These statements may be
identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate" and "intend," among
others. Such forward-looking statements are based on the currently
held beliefs and assumptions of the management of Biofrontera AG,
which are expressed in good faith and, in their opinion,
reasonable. Forward-looking statements involve known and unknown
risks, uncertainties and other factors, which may cause the actual
results, financial condition, performance, or achievements of the
Company, or industry results, to differ materially from the
results, financial condition, performance or achievements expressed
or implied by such forward-looking statements. These risks,
uncertainties and other factors are set forth in the Registration
Statement on Form F-1 filed with the SEC, including in the section
"Risk Factors," and in future reports filed with the SEC. Given
these risks, uncertainties and other factors, prospective investors
are cautioned not to place undue reliance on these forward-looking
statements. The Company does not undertake an obligation to update
or revise any forward-looking statement.
For enquiries, please contact:
Biofrontera AG
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0
ir@biofrontera.com
IR UK: Seton Services
Toni Vallen
+44 (0) 207 224 8468
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas
+1 646-536-7035
+1 508-280-6592
Biofrontera (NASDAQ:BFRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biofrontera (NASDAQ:BFRA)
Historical Stock Chart
From Sep 2023 to Sep 2024